An ecosystem that enabled seamless relocation and access to resources unavailable elsewhere
From a university laboratory in Belfast, a small biotech company is preparing to ask the oldest question in medicine: does the theory hold in the human body? CV6 Therapeutics, born in California and remade in Northern Ireland, has secured nearly £8 million to carry its novel cancer drug into first-in-human trials — a moment that speaks not only to scientific ambition but to the quiet power of institutional welcome. The drug, designed to wound cancer cells and awaken the immune system simultaneously, now enters the slow, rigorous passage from promise to proof.
- A cancer drug developed inside a university lab — rare in an industry dominated by pharmaceutical giants — is crossing the threshold into human testing for the first time.
- The stakes are high: Phase 1a trials must first establish that the drug is safe before any question of efficacy can even be asked.
- Nearly £8 million has been assembled from a web of public agencies, European funds, and private investors to make these trials possible.
- Belfast Health and Social Care Trust will host the trials, meaning local patients could become the first in the world to receive the treatment.
- The company's unlikely relocation from California to Belfast — prompted by a single invitation from a university vice-chancellor — now positions Northern Ireland as a potential hub for oncology innovation.
A Belfast biotech company is preparing to test a novel cancer drug in human patients for the first time, backed by nearly £8 million in investment. CV6 Therapeutics, based at Queen's University, has developed a treatment designed to work alongside conventional therapies — damaging cancer cell DNA while simultaneously activating the immune system to amplify the anti-cancer response. The company is now entering Phase 1a clinical trials, focused on establishing safety, optimal dosing, and early evidence of efficacy.
What gives this moment particular weight is the drug's origins. CV6 is one of the few oncology treatments to emerge from a UK university laboratory rather than a pharmaceutical giant. The company was founded in California in 2013 but relocated to Queen's University after an invitation from the institution's then vice-chancellor, Patrick Johnston. In Northern Ireland, CV6 found a supportive ecosystem — backing from Queen's, research assistance from Invest NI, and investment from QUBIS, the university's commercialisation arm.
The funding behind the trial reflects this layered support. CV6 raised over £5 million from Invest NI, QUBIS, CoFund NI, Techstart Ventures, and private investors on both sides of the Atlantic. Invest NI also awarded a separate £3 million R&D grant, itself partly financed through the European Regional Development Fund.
Founder and CEO Dr. Robert Ladner credited the institutional environment for the company's growth, noting that the move from California enabled skilled local hiring and access to resources unavailable elsewhere. The trials will run through the Belfast Experimental Cancer Medicine Centre, giving local patients early access to the treatment. Ladner suggested the work could reframe Belfast's identity as a serious centre for cancer research — and for CV6-168, the compound's designated name, human trials represent the moment when that ambition meets reality.
A Belfast-based biotech company is preparing to test a novel cancer drug in human patients for the first time, backed by nearly £8 million in fresh investment. CV6 Therapeutics, housed at Queen's University, has developed a treatment designed to work alongside conventional cancer therapies—damaging cancer cell DNA while simultaneously triggering the immune system to amplify the anti-cancer response. The company is now moving into Phase 1a clinical trials, a critical early stage focused on establishing safety, measuring how the body processes the drug, pinpointing the right dose, and gathering preliminary evidence of whether it actually works against tumors.
What makes this moment significant is where the drug was developed. CV6 is one of the few oncology treatments to emerge from a UK university laboratory rather than a pharmaceutical giant or standalone biotech firm. The company's journey to Belfast is itself a small story of scientific migration. Founded in California in 2013, CV6's research team relocated to Queen's University after receiving an invitation from the institution's then vice-chancellor, Patrick Johnston. That move proved consequential. The company found in Northern Ireland what it described as a "friendly" support ecosystem—backing from Queen's itself, research and development assistance from the economic development agency Invest NI, and investment from QUBIS, Queen's commercialisation arm.
The financial architecture behind the trial reflects this layered support. CV6 has raised over £5 million from a mix of sources: Invest NI, QUBIS, CoFund NI (managed by Clarendon Fund Managers), Techstart Ventures, and both American and local private investors. On top of that, Invest NI awarded the company a £3 million research and development grant specifically to fund the clinical trial work. That grant itself carries European backing, financed in part through the European Regional Development Fund under the EU Investment for Growth and Jobs Programme.
Dr. Robert Ladner, CV6's founder and chief executive, framed the company's success as inseparable from the institutional environment that surrounded it. He noted that moving from California to Belfast allowed the team to expand with skilled local hires and access financial and scientific resources that would have been unavailable elsewhere. He emphasized that Queen's University's established reputation for industry collaboration made it an unusually attractive destination for a US-based company seeking to relocate. The clinical trials themselves will take place through the Belfast Health and Social Care Trust, specifically via the Belfast Experimental Cancer Medicine Centre, meaning local patients will have the opportunity to participate in early-stage testing of the drug.
Ladner suggested the drug could reshape perceptions of Belfast as a center for cancer research and pharmaceutical development. CV6-168, as the compound is designated, has potential across multiple cancer types, he said, and entering human trials represents a watershed moment for the company. Queen's University vice-chancellor Professor Ian Greer characterized the milestone as validation of the institution's approach—integrating clinicians, life scientists, and data scientists with industry partners to develop new treatments and diagnostic tools. Brian McCaul, CEO of QUBIS, described the investment in CV6 as a vote of confidence in Northern Ireland's broader biotech and life sciences sector.
The trial will now determine whether the theoretical promise of the drug translates into clinical reality. Safety data will come first. Researchers will measure absorption rates, establish optimal dosing, and watch for adverse effects. Only then will they begin to assess whether the drug actually delivers on its anti-cancer potential. For Belfast, for Queen's University, and for the patients who may eventually enroll, the next phase of CV6's story is about to begin.
Notable Quotes
The ecosystem here enabled us to seamlessly move our team over from California, add highly skilled people to that team and tap into several financial and scientific benefits we would not have been able to access elsewhere.— Dr. Robert Ladner, founder and CEO of CV6 Therapeutics
It is through integrating the activities of clinicians, life scientists and data scientists with industry partners that we are able to make a huge impact to improve cancer treatment.— Professor Ian Greer, vice-chancellor of Queen's University
The Hearth Conversation Another angle on the story
Why does it matter that this drug was developed at a university rather than in a traditional pharma lab?
Universities move slowly, but they move differently. There's less pressure to hit quarterly targets, more room for the kind of basic research that sometimes leads nowhere and sometimes leads here. It also signals something about the UK's scientific infrastructure—that cancer drug development isn't confined to London or Cambridge anymore.
The company moved from California to Belfast. That's unusual. What made that attractive?
Queen's had a reputation for actually helping companies, not just housing them. And Northern Ireland offered something California couldn't: coordinated support from government, the university, and investment arms all working in the same direction. For a young company, that alignment matters enormously.
What happens in Phase 1a trials?
It's the most cautious step. You're not trying to cure anyone yet. You're asking: Is this safe? How does the body handle it? What dose doesn't poison people? You're gathering the basic facts before you can even ask whether it works.
The funding structure is complex—grants, private investors, European money. Why so many sources?
No single funder wants to carry all the risk. Universities invest because it's their mission. Government agencies invest because it builds the sector. Private investors invest because they see potential returns. European money comes because the region qualifies for development support. It's a ecosystem, not a transaction.
If this works, what changes?
Belfast becomes a place where cancer patients can access cutting-edge trials. The university's reputation for biotech grows. Other companies look at CV6 and think: maybe we should be there too. And the people who built this—they stay, they hire, they build more.